Modified release formulations of memantine oral dosage forms

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8039009
APP PUB NO 20060051416A1
SERIAL NO

11155330

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
FOREST LABORATORIES HOLDINGS LIMITEDHAMILTON54

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Abramowitz, Wattanaporn Hillsborough, US 18 60
Dedhiya, Mahendra G Pomona, US 61 199
Mahashabde, Shashank Kendall Park, US 20 37
Periclou, Antonia Jersey City, US 19 85
Rao, Niranjan Belle Mead, US 22 85
Rastogi, Suneel K Island Park, US 17 61

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
2004/0102,525 Compositions and methods of treating neurological disease and providing neuroprotection 66 2003
 
KENRICO LTD (1)
6413556 Aqueous anti-apoptotic compositions 11 2000
 
PANORAMA RESEARCH, INC. (1)
6444702 Aminoadamantane derivatives as therapeutic agents 18 2000
 
ADAMAS PHARMA, LLC (1)
2006/0142,398 Method and composition for adminstering an NMDA receptor antagonist to a subject 27 2005
 
DepoMed Systems, Inc. (1)
5007790 Sustained-release oral drug dosage form 191 1989
 
CHILDREN'S MEDICAL CENTER CORPORATION (3)
5334618 Method of preventing NMDA receptor-mediated neuronal damage 30 1992
5506231 Treatment of aids dementia, myelopathy and blindness 11 1993
5614560 Method of preventing NMDA receptor-mediated neuronal damage 43 1995
 
GATX VENTURES, INC. (2)
5582837 Alkyl-substituted cellulose-based sustained-release oral drug dosage forms 124 1995
5972389 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter 172 1996
 
MERZ PHARMA GMBH & CO. KGAA (4)
5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 42 1990
5382601 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof 39 1993
6034134 1-Amino-alkylcyclohexane NMDA receptor antagonists 59 1998
6071966 1-amino-alkylcyclohexane NMDA receptor antagonists 13 1998
 
MAYNE PHARMA INTERNATIONAL PTY. LTD. (1)
6194000 Analgesic immediate and controlled release pharmaceutical composition 120 1998
 
NEUROMOLECULAR, INC. (1)
2005/0245,617 Methods and compositions for the treatment of CNS-related conditions 29 2005
 
FOREST LABORATORIES HOLDINGS LIMITED (3)
2006/0002,999 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 16 2005
2007/0065,512 MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE 28 2006
2009/0247,644 MEMANTINE FORMULATIONS 1 2009
 
ASTRAZENECA AB (1)
6479553 Use of certain affinity NMDA antagonists as antidepressants 25 2000
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
ADAMAS PHARMA, LLC (1)
8741343 Method of administering amantadine prior to a sleep period 8 2010
 
THE GENERAL HOSPITAL CORPORATION (1)
9242009 Compositions and methods to treat neurodegenerative diseases 0 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 18, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 18, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00